A TCR recognizing an HLA-A*0201-restricted peptide derived from PLAC1 was recently isolated and shown to possess antitumor activity against human breast cancer cells in pre-clinical models, but have not yet been tested in clinical trials58. This evidence concerns the gene PLAC1 and breast cancer.